Seeing is Believing... Look Beneath the Surface
|
|
- Amberlynn Atkins
- 6 years ago
- Views:
Transcription
1 References 1. Idee JM, Port C, Raynal I, et al. Clinical and geological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundamental and Clinical Pharmacology. 200; 20: Prince M., et al. Gadodiamide Administration Causes Spurious Hypocalcemia Radiol. 2003; 227, 3: Tweedle MF, Wedeking P, Kumar K. Biodistribution of Radiolabeled, Formulated Gadopentetate, Gadoteridol, Gadoterate, and Gadodiamide in Mice and Rats. Invest Radiol. 1995; 30; Gibby WA, Gibby KA, Gibby WA. Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-D03A (ProHance) Retention in Human Bone Tissue by Inductively Coupled Plasma Atomic Emission Spectroscopy. Invest Radiol. 2004; 39: Kirchin M, Runge V, Contrast Agents for Magnetic Resonance Imaging Safety Update. Top Magn Reson Imaging. 2003;14:5. ProHance (gadoteridol) injection mg/ml full Prescribing Information. Princeton, NJ: Bracco Diagnostics Inc.; May Omniscan (gadodiamide) injection, full Prescribing Information. Princeton, NJ: GE HealthCare Inc.; June OptiMARK (gadoversetamide injection) full Prescribing Information. St. Louis, MO: Mallinckrodt Inc.; May Magnevist (brand of gadopentetate dimeglumine) injection full Prescribing Information. Wayne, NJ: Bayer Healthcare Pharmaceuticals Inc.; June MultiHance (gadobenate dimeglumine) injection 529 mg/ml full Prescribing Information. Princeton, NJ: Bracco Diagnostics Inc.; May Emerson J. et al. Spurious Hypocalcemia after Omniscan- or OptiMARK-Enhanced Magnetic Resonance Imaging. Arch Pathol Lab Med. 2004; Vol 128: For more medical information, call Bracco Professional Services: Option 2 For more information about ProHance, visit For more information about Bracco Products, visit or call Bracco Customer Service BRACCO-9 ( ) ProHance is a registered trademark of Bracco Diagnostics Inc. MultiHance is a registered trademark of Bracco Diagnostics Inc. Magnevist is registered trademark of Bayer HealthCare Phamaceuticals Inc. Omniscan is a trademark of GE Healthcare Inc. OptiMARK is a registered trademark of Covidien. BDI Seeing is Believing... Look Beneath the Surface
2 Seeing is Believing... Look Beneath the Surface Of the gadolinium-based contrast agents available for use in the U.S.: ~ ProHance is the first and only macrocyclic and nonionic agent. ~ ProHance has the highest thermodynamic stability constant, conditional stability and lowest osmolality of the nonionic agents1 (Refer to chart on page 4). ~ ProHance is the only nonionic MRI agent that does not interfere with colorimetric serum calcium determinations. 2 acute or chronic severe renal insufficiency (glomerular filtration rate <30mL/min/1.73m2), or
3 Observe the stability of ProHance ProHance, with its macrocyclic molecular structure, has the highest thermodynamic stability constant and conditional stability of the nonionic gadolinium-based MR contrast agents available in the U.S. 1,3,4,5 The Only Nonionic Contrast Agent That Does Not Interfere with Serum Calcium Determinations by Colorimetric Methods 2,11 ProHance (gadoteridol) Omniscan (gadodiamide) 7 OptiMARK (gadoversetamide) 8 Magnevist (gadopentetate dimeglumine) 9 MultiHance (gadobenate dimeglumine) 10 Molecular 5 Gadoteridol Structure Macrocyclic Linear Linear Linear Linear (ProHance ) 4 Gadovesetamide Ionicity Nonionic Nonionic Nonionic Ionic Ionic 3 (OptiMARK ) 4 Osmolality 2 Gadodiamide (mosm/kg, 37ºC) (Omniscan ) 1 Viscosity (cp, OptiMark Omniscan 37ºC) Maximum Adult Dose (mmol/kg) Thermodynamic Stability Constant (ph=1.0) Conditional Stability (ph=7.4) Dissociation half-life (@25 C in 0.1 N HCI) Amount of excess chelate h 35 sec Not Available 10 min Not Available Serum Calcium mg/dl ProHance Magnevist (Gd)mM Chart taken from Prince M., et al. Gadodiamide Administration Causes Spurious Hypocalcemia Radiology 2003; 227, 3: 39-4 *Magnevist is an ionic agent ~ In one clinical study with ProHance and Omniscan, false hypocalcemia was noted in 15.7% of 1049 examinations performed with Omniscan. 2 ~ In the same study, 25 examinations (2.4%), the decreases in serum calcium readings resulted in measurements of critical hypocalcemia, resulting in inappropriate and potentially dangerous calcium therapy in 18 patients. 2 Saline Gadopentate dimegiumine acute or chronic severe renal insufficiency (glomerular filtration rate <30mL/min/1.73m 2 ), or
4 Observe the qualities of ProHance See how ProHance helps you do more ProHance is the only macrocyclic gadolinium-based contrast agent approved for pediatric use in the U.S. Standard Dose ProHance is indicated for use in MRI in children over 2 years of age to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues. A B C Courtesy of Zoarsky GH, Center for the Health Sciences, UCLA 7 A) T1-weighted precontrast image shows a rounded mass in the jugular foramen region. B) T2-weighted image shows the same mass. C) T1-weighted image after 0.1 mmol/kg ProHance administration shows bright heterogeneous enhancement of the tumor, characteristic of Schwannoma. ProHance is indicated for use in MRI in adults: ~ to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues. ~ to visualize lesions in the head and neck. acute or chronic severe renal insufficiency (glomerular filtration rate <30mL/min/1.73m2), or
5 ProHance packaging options ProHance is available in 5, 10, 15, 20mL single-dose vials, and 50mL Multipack * (Pharmacy Bulk Packages). Additionally, ProHance is available in prefilled syringes in 10mL and 17mL fill sizes. 8 9 ProHance Ordering Information * Not for Direct Infusion acute or chronic severe renal insufficiency (glomerular filtration rate <30mL/min/1.73m2), or Five 5mL vials Five 10mL vials Five 15mL vials Five 20mL vials Five 10mL prefilled syringes Five 17mL prefilled syringes mL Multipack* * Not for Direct Infusion
6 Why ProHance? ~ High chelate stability reduces interference with calcium testing. 2,11 ~ Indicated for use in CNS MRI for adults and pediatric patients as young as 2 years old. ~ Flexible packaging options ~ The clinical experience of ProHance exceeds 10 million doses safely administered worldwide. 10 acute or chronic severe renal insufficiency (glomerular filtration rate <30mL/min/1.73m 2 ), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period. In these patients, avoid the use of gadolinium-based contrast agents unless the diagnostic information is essential and not available with non-contrast enhanced magnetic resonance imaging (MRI). NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle or internal organs. Screen all patients for renal dysfunction by obtaining a history and/or laboratory tests. When administering a gadolinium-based contrast agent, do not exceed the recommended dose and allow a sufficient period of time of elimination of the agent from the body prior to any readministration. As with all paramagnetic agents, caution should be exercised in patients with deoxygenated sickle erythrocytes and renal insufficiency with or without hepatic impairment. The possibility of a reaction, including serious, life threatening, or fatal, anaphylactic or cardiovascular reactions, or other idiosyncratic reactions, should always be considered, especially in those patients with a history of a known clinical hypersensitivity or a history of asthma or other allergic respiratory disorders.
Gadolinium-Based Contrast Media
Gadolinium-Based Contrast Media Wm. Faulkner, B.S.,R.T.(R)(MR)CT, FSMRT, MRSO (MRSC ) Kristan Harrington, MBA, R.T.(R)(MR), MRSO (MRSC TM ) Gadolinium ( 64 Gd) 7 un-paired electrons chelate, any of a class
More informationINTRODUCTION CLINICAL EXPERIENCE CLINICAL EFFICACY PEDIATRIC EXPERIENCE DOSING SUMMARY
1 2 DOTAREM Administered Doses 3 Molecular Structure of DOTAREM DOTAREM offers high thermodynamic and kinetic stability provided by its macrocyclic and ionic structure* 3 *The clinical significance of
More informationMR Contrast Agents. Why Use Contrast Agents in MRI? Why Use Contrast Agents in MRI? US Agents. Understanding and Embracing Change
Why Use Contrast Agents in MRI? Improve disease detection and characterization Increase sensitivity to extent of disease MR Contrast Agents Understanding and Embracing Change Kristan Harrington, MBA, RT
More informationPlease see Important Safety Information, including Boxed Warnings for Gadavist and Magnevist below.
August 15 th, 2018 Dear Valued Customer: Thank you for your continued patience over the last several months as we have worked to resolve our contrast supply interruption. The purpose of this letter is
More informationGadolinium Based Contrast Agent Recommendations (Revised 06/07/2018)
Gadolinium Based Contrast Agent Recommendations (Revised 06/07/2018) Introduction: Nephrogenic systemic fibrosis is the only known adverse health effect related to gadoliniumbased contrast agents (GBCAs).
More informationGadolinium-Based MR Contrast Agents
Gadolinium-Based MR Contrast Agents Wm. Faulkner, BS,RT(R)(MR)(CT), FSMRT, MRSO (MRSC ) Kristan Harrington, MBA, RT(R)(MR) ARRT, MRSO (MRSC ) Magnetic Resonance Imaging, Vol 3, pp27-35, 1985 0.35 T 35/1600
More informationA Safety Update on the Gadolinium Chelates
Control # 1029 A Safety Update on the Gadolinium Chelates Val M. Runge, MD Universitätsinstitut für Diagnostische, Interventionelle und Pädiatrische Radiologie University Hospital Bern Allergic Reactions
More informationPlease see Important Safety Information, including Boxed Warnings for Gadavist, Eovist and Magnevist on the following pages.
Dear Valued Customer: As a valued partner we want to inform you that a technical issue occurred at our Berlin manufacturing center where final formulation and packaging of Bayer MRI (Magnetic Resonance
More informationGadolinium-Based Contrast Agents for Magnetic Resonance Imaging (marketed as Magnevist, MultiHance, Omniscan, OptiMARK, ProHance)
Information for Healthcare Professionals Page 1 of 5 FDA ALERT [6/2006, updated 12/2006 and 5/23/2007: This updated Alert highlights FDA s request for addition of a boxed warning and new warnings about
More informationAdministration of Gadolinium Contrast in Adults Procedural Guideline
Administration of Gadolinium Contrast in Adults Procedural Guideline This procedural guideline is designed to assist Radiologists by providing an analytical framework for the evaluation of gadolinium contrast
More informationImportant Update - Availability of Bayer s MRI (Magnetic Resonance Imaging) Contrast agents
Important Update - Availability of Bayer s MRI (Magnetic Resonance Imaging) Contrast agents Certain batches of pharmaceutical products from our company s Supply Center in Berlin where final formulation
More informationGadolinium-Based MR Contrast Agents
Gadolinium-Based MR Contrast Agents Magnetic Resonance Imaging, Vol 3, pp27-35, 1985 Wm. Faulkner, BS,RT(R)(MR)(CT), FSMRT, MRSO (MRSC ) Kristan Harrington, MBA, RT(R)(MR) ARRT, MRSO (MRSC ) 0.35 T 0.35
More informationBeyond NSF: Acute GBCA adverse reactions
Source images Beyond NSF: Acute GBCA adverse reactions Martin R. Prince, MD, PhD, FACR Disclosures Patent Agreements: GE, Siemens, Philips, Hitachi, Toshiba, Bayer, Bracco, Mallinckrodt, Medrad, Nemoto,
More informationGlobal reports and findings of NSF and its effects
Safety Forum: MR Safety Update - SMRT 2008 Sunday May 8, 2:25 p.m. Global reports and findings of NSF and its effects Tim Leiner, MD PhD Assistant Professor of Radiology, Department of Radiology, Maastricht
More informationNSF Coming and Going
NSF Coming and Going Martin R. Prince, MD, PhD Cornell and Columbia Universities Patent agreements: GE, Philips, Siemens, Hitachi, Medrad, Epix, Lantheus, Bayer, Bracco, Nemoto, Mallinckrodt and Topspins
More informationPATIENT CARE AND MRI SAFETY Module 7
PATIENT CARE AND MRI SAFETY Module 7 1 Biological Considerations There are no reported adverse biological effects of extended exposure to MRI. However, several inconsequential and reversible effects of
More informationExtracellular gadolinium-based contrast media: An overview
European Journal of Radiology 66 (2008) 160 167 Extracellular gadolinium-based contrast media: An overview Marie-France Bellin, Aart J. Van Der Molen University Paris-Sud 11, Department of Radiology, University
More informationUniversity of Virginia Institutional Review Board - Health Sciences Research Guidelines for Researchers Using Gadolinium-Enhanced MRI in Research
University of Virginia Institutional Review Board - Health Sciences Research Guidelines for Researchers Using Gadolinium-Enhanced MRI in Research Page 1 of 16 Table of Contents New Information:... 3 IRB-HSR
More information1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION. 1.1 Central Nervous System. 1.2 Extracranial/Extraspinal Tissues. 1.3 Body
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use MAGNEVIST safely and effectively. See full prescribing information for MAGNEVIST. MAGNEVIST (gadopentetate
More informationProtocol for iv. iodine and gadolinium contrast studies
Protocol for iv. iodine and gadolinium contrast studies Royal College of Radiologists Standard The individual administering the contrast agent must ensure that the patient understands that it is to be
More informationFigure 1 Figure 1: Energy diagram illustrates formation of a chelate (ML) created by combining two chemicals free Gd 3 (M), which is a metal ion, and
Note: This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues or clients, use the Radiology Reprints form at the end of this article.
More informationInformation for Healthcare Professionals and other Stakeholders
Information for Healthcare Professionals and other Stakeholders NEPHROGENIC SYSTEMIC FIBROSIS: AN UNCOMMON AND DEBILITATING DISEASE POSSIBLY ASSOCIATED WITH GADOLINIUM CHELATES Villepinte, February 2014
More informationPRODUCT MONOGRAPH GADOVIST 1.0. gadobutrol injection 604 mg/ml (1.0 mmol/ml) For Intravenous Use
PRODUCT MONOGRAPH GADOVIST 1.0 gadobutrol injection 604 mg/ml (1.0 mmol/ml) For Intravenous Use Contrast Enhancement Agent for Magnetic Resonance Imaging (MRI) For Professional Use Only Bayer Inc. Date
More informationPRODUCT MONOGRAPH DOTAREM. (gadoterate meglumine) Injection. For Intravenous Use
PRODUCT MONOGRAPH DOTAREM (gadoterate meglumine) Injection For Intravenous Use Gadolinium-Based Contrast Agent For Use with Magnetic Resonance Imaging (MRI) Guerbet LLC Date: August 26, 2013 120 W. 7 th
More informationContrast-enhanced MRI: how do changing EU regulations impact daily practice?
Safety considerations in contrast enhanced procedures Carlo Catalano Sapienza University of Rome Contrast-enhanced MRI: how do changing EU regulations impact daily practice? CE MRI: EU regulations - Initial
More informationDIVISION OF MEDICAL IMAGING AND HEMATOLOGY PRODUCTS
DIVISION OF MEDICAL IMAGING AND HEMATOLOGY PRODUCTS MEMORANDUM TO THE FILE i. NDA: 20-123, 22-066 Product: Omniscan ii. NDA: 19-596, 21-037 Product: Magnevist iii. NDA: 20-976, 20-937,20-975 Product: OptiMARK
More informationAnnex III. Amendments to relevant sections of the product information
Annex III Amendments to relevant sections of the product information Note: These amendments to the relevant sections of the product information are the outcome of the referral procedure. The product information
More informationContrast media Purpose of using contrast Contrast reaction Nephrotoxicity from contrast Nephrogenic systemic fibrosis When should contrast be used
Contrast vs Non-Contrast When to Order Stephen McManus, M.D. Contrast media Purpose of using contrast Contrast reaction Nephrotoxicity from contrast Nephrogenic systemic fibrosis When should contrast be
More informationFDA Advisory Committee Briefing Document. Medical Imaging Drugs Advisory Committee. Meeting to be held on February 14, 2013
FDA Advisory Committee Briefing Document Medical Imaging Drugs Advisory Committee Meeting to be held on February 14, 2013 New Drug Application 204-781 Gadoterate meglumine Injection (Dotarem ), sponsored
More informationGadolinium Deposition in the Brain: Summary of Known Science and Recommendations from the International Society for Magnetic Resonance in Medicine
Gadolinium Deposition in the Brain: Summary of Known Science and Recommendations from the International Society for Magnetic Resonance in Medicine Vikas Gulani, MD, PhD 1-4*, Fernando Calamante, PhD 5,6,
More informationWilliam G. Bradley, Jr, MD, PhD, FACR
William G. Bradley, Jr, MD, PhD, FACR Professor of Radiology Chair, Dept of Radiology University of California, San Diego Medical Center San Diego, California Learning Objectives Identify emerging safety
More informationSee 17 for PATIENT COUNSELING INFORMATION and Medication Guide. flow rate of approximately 2 ml/second for adults and 1-2 ml/second for pediatric
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use DOTAREM safely and effectively. See full prescribing information for DOTAREM. DOTAREM (gadoterate
More informationDOTAREM (gadoterate meglumine) Injection for intravenous use Initial U.S. Approval: 2013
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use DOTAREM safely and effectively. See full prescribing information for DOTAREM. DOTAREM (gadoterate
More informationPRODUCT MONOGRAPH GADOVIST 1.0. gadobutrol injection 604 mg/ml (1.0 mmol/ml) For Intravenous Use
PRODUCT MONOGRAPH GADOVIST 1.0 gadobutrol injection 604 mg/ml (1.0 mmol/ml) For Intravenous Use Contrast Enhancement Agent for Magnetic Resonance Imaging (MRI) Bayer Inc. 77 Belfield Road Toronto, ON M9W
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION DOTAREM. Gadoterate meglumine injection. (376.9 mg/ml, equivalent to 0.
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION DOTAREM Gadoterate meglumine injection (376.9 mg/ml, equivalent to 0.5 mmol/ml) For Intravenous Use Contrast Enhancement Agent for Magnetic Resonance
More informationGadolinium Retention in the Dentate Nucleus and Globus Pallidus Is Dependent on the Class of Contrast Agent 1
Note: This copy is for your personal non-commercial use only. To order presentation-ready copies for distribution to your colleagues or clients, contact us at www.rsna.org/rsnarights. Alexander Radbruch,
More informationSUBJECT: ASSESSMENT OF LAB RESULTS PRIOR TO INJECTING GADOLINIUM-BASED CONTRAST MEDIA.
ASSESSMENT OF PATIENTS: IMAGING SERVICES Policy #: 300.02 Effective Date: 6/29/09 Last Revision Date: 10/07 Page 1 of 5 SUBJECT: ASSESSMENT OF LAB RESULTS PRIOR TO INJECTING GADOLINIUM-BASED CONTRAST MEDIA
More informationInformation for Healthcare Professionals and other Stakeholders
Information for Healthcare Professionals and other Stakeholders NEPHROGENIC SYSTEMIC FIBROSIS: AN UNCOMMON AND DEBILITATING DISEASE POSSIBLY ASSOCIATED WITH GADOLINIUM CHELATES Villepinte, April 2013 Any
More informationPRODUCT MONOGRAPH PRIMOVIST. gadoxetate disodium injection mg/ml (0.25 mmol/ml)
PRODUCT MONOGRAPH PRIMOVIST gadoxetate disodium injection 181.43 mg/ml (0.25 mmol/ml) Intravenous contrast enhancement agent for magnetic resonance imaging (MRI) For Professional Use Only Distributed and
More informationAnnex II. Scientific conclusions
Annex II Scientific conclusions 31 Scientific conclusions In accordance with Article 107k of Directive 2001/83/EC, the CHMP considered the PRAC recommendation adopted on 6 July 2017. Overall summary of
More informationGadolinium Magnetic Resonance Contrast Agents Produce Analytic Interference in Multiple Serum Assays
Clinical Chemistry / GDOLINIUM CONTRST GENT INTERFERENCE Gadolinium Magnetic Resonance Contrast gents Produce nalytic Interference in Multiple Serum ssays Kerry.S. Proctor, MD, 1 Lokinendi V. Rao, PhD,
More informationGadolinium in Humans: A Family of Disorders
Residents Section Clinical Perspective Semelka et al. Gadolinium in Humans Residents Section Clinical Perspective Residents inradiology Richard C. Semelka 1 Miguel Ramalho 1,2 Mamdoh AlObaidy 1,3 Joana
More informationFrequency and Severity of Acute Allergic-Like Reactions to Gadolinium-Containing IV Contrast Media in Children and Adults
Reactions to Gadolinium- Containing Contrast Media MR Imaging Original Research Jonathan R. Dillman 1 James H. Ellis 1 Richard H. Cohan 1 Peter J. Strouse 2 Sophia C. Jan 1 Dillman JR, Ellis JH, Cohan
More informationReport on the Investigation Results
This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translation, the former shall Report
More informationIncidence of Immediate Gadolinium Contrast Media Reactions
Health Care Policy and Quality Original Research Prince et al. Immediate Gadolinium Contrast Media Reactions Health Care Policy and Quality Original Research Martin R. Prince 1 Honglei Zhang Zhitong Zou
More informationPublic Assessment Report
Public Assessment Report Increased risk of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis and gadolinium-containing MRI contrast agents Executive summary 2 Introduction 3 Data assessed
More informationPRODUCT INFORMATION DOTAREM
PRODUCT INFORMATION DOTAREM NAME OF THE MEDICINE DOTAREM (gadoteric acid) paramagnetic contrast medium for Magnetic Resonance Imaging (MRI). The structural formula of gadoteric acid is shown below: The
More informationCONTRAINDICATIONS History of severe hypersensitivity reaction to EOVIST (4)
HIGHLIGHTS F PRESCRIBING INFRMATIN These highlights do not include all the information needed to use EVIST safely and effectively. See full prescribing information for EVIST Injection. EVIST (gadoxetate
More informationFULL PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use MAGNEVIST safely and effectively. See full prescribing information for MAGNEVIST. MAGNEVIST (gadopentetate
More informationReference ID: MultiHance Injection, NDA , SAFETY LABELING CHANGES UNDER 505(o)(4) MultiHance PI to FDA_Revised Nov _CLEAN.
MultiHance Injection, NDA 21-357, SAFETY LABELING CHANGES UNDER 505(o)(4) MultiHance PI to FDA_Revised Nov-18-2010_CLEAN.doc HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the
More informationSummary. Correspondence Jerrold L. Abraham. Accepted for publication 17 September 2007
CLINICAL AND LABORATORY INVESTIGATIONS DOI 10.1111/j.1365-2133.2007.08335.x Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic
More informationInformation for Healthcare Professionals and other Stakeholders
Information for Healthcare Professionals and other Stakeholders NEPHROGENIC SYSTEMIC FIBROSIS: AN UNCOMMON AND DEBILITATING DISEASE POSSIBLY ASSOCIATED WITH GADOLINIUM CHELATES Villepinte, 2 july 2008
More informationHepatobiliary Contrast Agents for Liver MRI
Hepatobiliary Contrast Agents for Liver MRI Scott B. Reeder, MD, PhD International Society for Magnetic Resonance in Medicine Sociedad Mexicana de Radiologia e Imagen (SMRI) Mexico City June 4, 2014 Department
More informationflow rate of approximately 2 ml/second for adults and 1-2 ml/second for pediatric patients. The dose is delivered by manual or power injection.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use DOTAREM safely and effectively. See full prescribing information for DOTAREM. DOTAREM (gadoterate
More informationImaging in the time of NFD/NSF: do we have to change our routines concerning renal insufficiency?
DI 10.1007/s10334-007-0071-5 EDITRIAL REVIEW Imaging in the time of FD/SF: do we have to change our routines concerning renal insufficiency? Georg Bongartz Accepted: 7 March 2007 ESMRMB 2007 Abstract To
More informationSafety and clinical usefulness of gadoteric acid including post-marketing surveillance
Safety and clinical usefulness of gadoteric acid including post-marketing surveillance MRI is an essential diagnostic tool in making definite diagnoses and determining therapeutic strategies. Extracellular
More informationMagnetic resonance (MR) imaging
This copy is for personal use only. To order printed copies, contact reprints@rsna.org Reviews and Commentary n Opinion Carlo Cosimo Quattrocchi, MD, PhD Aart J. van der Molen, MD Published online 10.1148/radiol.2016161626
More informationBilling Guide. For Freestanding Imaging Centers Provided by Bayer HealthCare
Billing Guide For Freestanding Imaging Centers Provided by Bayer HealthCare Introduction Bayer HealthCare Inc. offers this billing guide to freestanding imaging center customers as part of its comprehensive
More informationIL PROBLEMA DEL GADOLINIO OGGI
11-12 Maggio 2018 Rimini IL PROBLEMA DEL GADOLINIO OGGI Il punto di vista del Neuroradiologo pediatrico Dott.ssa Camilla Rossi Espagnet U.O. Neuroradiologia, Dipartimento Immagini, Ospedale Pediatrico
More informationCONTRAINDICATIONS Clinically important hypersensitivity reactions to DOTAREM. (4)
M120177AB HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use DOTAREM safely and effectively. See full prescribing information for DOTAREM. DOTAREM (gadoterate
More informationGadolinium Deposition:
Gadolinium Deposition: Imaging Phenomenon or Should we change practice? Gregory Brown FSMRT MR Radiographer, PhD student Centre for Advanced Imaging, University of Queensland, Australia ORCID: 0000-0001-7994-2743
More informationInstructions for the safe administration of gadolinium based contrast agents (GBCA). 1. PREADMINISTRATION PRECAUTIONS:
POLICY NUMBER: RM 6-18 CATEGORY: Patient Care DATE: June 2016 NEXT REVIEW DATE: April 2017 SUBJECT: PURPOSE: POLICY: Intravenous Gadolinium Based Contrast Administration To prevent complications associated
More informationDOTAREMÂ - gadoterate meglumineâ injectionâ Guerbet LLC
DOTAREMÂ - gadoterate meglumineâ injectionâ Guerbet LLC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use DOTAREM safely and effectively.
More informationReference ID:
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use DOTAREM safely and effectively. See full prescribing information for DOTAREM. DOTAREM (gadoterate
More informationSafety of Gadoterate Meglumine (Gd-DOTA) as a Contrast Agent for Magnetic Resonance Imaging
ORIGINAL RESEARCH ARTICLE Drugs R D 2010; 10 (3): 133-145 1179-6901/10/0003-0133 ª 2010 Ishiguchi & Takahashi, publisher and licensee Adis Data Information BV. This is an open access article published
More informationT1 Relaxivities of Gadolinium-Based Magnetic Resonance Contrast Agents in Human Whole Blood at 1.5, 3, and 7 T
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2015 T1 Relaxivities of Gadolinium-Based Magnetic Resonance Contrast Agents
More informationRadiology Reimbursement Information Setting: Hospital Outpatient
Radiology Reimbursement Information Setting: Hospital Outpatient About DOTAREM: DOTAREM is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain
More informationSide Effects and Complications of Magnetic Resonance Contrast Media
HOSPITAL CHRONICLES 2012, 7(4): 208 214 Review Side Effects and Complications of Magnetic Resonance Contrast Media Ekaterini Tavernaraki, MD, PhD, Anna Skoula MD, Stylianos Benakis, MD, Dimitrios Exarhos
More informationGadolinium and nephrogenic systemic fibrosis
mini review http://www.kidney-international.org & 2007 International Society of Nephrology Gadolinium and nephrogenic systemic fibrosis T Grobner 1 and FC Prischl 2 1 2nd Department of Medicine/Nephrology,
More informationPLEASE SCROLL DOWN FOR ARTICLE
This article was downloaded by:[danish Veterinary and Agricultural Library] [Danish Veterinary and Agricultural Library] On: 24 June 2007 Access Details: [subscription number 773444395] Publisher: Informa
More informationClinical Safety and Diagnostic Value of the Gadolinium Chelate Gadoterate Meglumine (Gd-DOTA)
ORIGINAL ARTICLE Clinical Safety and Diagnostic Value of the Gadolinium Chelate Gadoterate Meglumine (Gd-DOTA) Christoph U. Herborn, MD,* Elmar Honold, MD, Michael Wolf, Jörn Kemper, MD, Sonja Kinner,
More informationThis copy is for personal use only. To order printed copies, contact Purpose: Materials and Methods: Results: Conclusion:
This copy is for personal use only. To order printed copies, contact reprints@rsna.org No Incidence of Nephrogenic Systemic Fibrosis after Gadobenate Dimeglumine Administration in Patients Undergoing Dialysis
More informationNephrogenic systemic fibrosis associated with gadolinium based contrast agents: A summary of the medical literature reporting
European Journal of Radiology 66 (2008) 230 234 Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: A summary of the medical literature reporting Dale R. Broome Department of
More informationMinimizing Risk of Nephrogenic systemic fibrosis in Cardiovascular Magnetic Resonance
Reiter et al. Journal of Cardiovascular Magnetic Resonance 2012, 14:31 REVIEW Open Access Minimizing Risk of Nephrogenic systemic fibrosis in Cardiovascular Magnetic Resonance Theresa Reiter 1*, Oliver
More informationPublic Assessment Report for paediatric studies submitted in accordance with Article 45 and 46 of Regulation (EC) No1901/2006, as amended
Public Assessment Report for paediatric studies submitted in accordance with Article 45 and 46 of Regulation (EC) No1901/2006, as amended Gadopentetic acid (Gadopentate) Magnevist UK/W/049/pdWS/001 Rapporteur:
More informationGadolinium Use in Patients with Kidney Disease: A Cause for Concern
Editorial Gadolinium Use in Patients with Kidney Disease: A Cause for Concern Mark A. Perazella* and Roger A. Rodby *Section of Nephrology, Department of Medicine, Yale University School of Medicine, New
More informationMagnetic resonance imaging (MRI) scans are significantly
Mini-Review Current Status of Gadolinium Toxicity in Patients with Kidney Disease Mark A. Perazella Department of Medicine, Section of Nephrology, Yale University School of Medicine, New Haven, Connecticut
More informationDATA SHEET MAGNEVIST. Solution for Intravenous Injection Dimeglumine gadopentetate 0.5 mmol/ml PRESENTATION
DATA SHEET MAGNEVIST Solution for Intravenous Injection Dimeglumine gadopentetate 0.5 mmol/ml PRESENTATION Magnevist injection is a sterile, clear, colourless to slightly yellow solution for intravenous
More informationPATIENT INFORMATION LEAFLET. DOTAREM mg/ml, solution for injection (Gadoteric acid)
PATIENT INFORMATION LEAFLET DOTAREM 279.32 mg/ml, solution for injection (Gadoteric acid) Read all this leaflet carefully before you start using this medicine because it contains important information
More informationPRAC recommendations on signals for update of the product information
Thursday 22 January 2015 EMA/PRAC/62352/2015 Pharmacovigilance Risk Assessment Committee PRAC recommendations on signals for update of the product information Adopted at the 6-9 January 2015 PRAC 1. Atorvastatin,
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT DOTAREM 0.5 mmol/ml solution for injection in vials 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml solution for injection contains
More informationSpecial Articles Original Research
Special Articles Original Research Soulez et al. NSF in Patients With Stage 3 5 CKD Undergoing MRI With GBCA Special Articles Original Research Gilles Soulez 1 Daniel C. Bloomgarden 2,3 Neil M. Rofsky
More informationRenal Tolerance of a Neutral Gadolinium Chelate (gadobutrol) in Patients with Chronic Renal Failure: Results of a Randomized Study 1
Contrast Media Bernd Tombach, MD Christoph Bremer, MD Peter Reimer, MD Klaus Kisters, MD Roland M. Schaefer, MD Viviane Geens, MD Walter Heindel, MD Index terms: Gadolinium Kidney, failure, 81.699 Kidney,
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT DOTAREM 0.5 mmol/ml (for multiple use) solution for injection in vials 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml solution for
More informationPoster No.: B-229 Congress: ECR 2011 Scientific Paper. Authors: E. De Kerviler 1, S. Gaillard 2 ; 1 Paris/FR, 2 Villepinte/FR
Pharmacovigilance based on spontaneous adverse event reporting of meglumine gadoterate (Gd-DOTA) after 15 million administrations and 20 years of clinical use Poster No.: B-229 Congress: ECR 2011 Type:
More informationAPIDRA (insulin glulisine) injection vial APIDRA SOLOSTAR (insulin glulisine) subcutaneous solution pen-injector
APIDRA SOLOSTAR (insulin glulisine) subcutaneous solution pen-injector Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationPRODUCT INFORMATION NAME OF THE MEDICINE DESCRIPTION. GADOVIST 1.0 (gadobutrol) Physico-chemical properties
PRODUCT INFORMATION GADOVIST 1.0 (gadobutrol) NAME OF THE MEDICINE Gadovist 1.0 injection is a 1.0 mmol/ml solution of 10-(2,3-Dihydroxy-1- hydroxymethylpropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic
More informationUpdate. Drug Safety. Welcome to the first issue of the newly launched Drug Safety Update. This
Latest advice for medicines users The monthly newsletter from the Medicines and Healthcare products Regulatory Agency and its independent advisor the Commission on Human Medicines Volume 1, Issue 1 August
More informationPerfusion MRI: The Five Most Frequently Asked Technical Questions
Perfusion MRI Neuroradiology/Head and Neck Imaging Review Neuroradiology/Head and Neck Imaging Review FOCUS ON: Marco Essig 1 Mark S. Shiroishi 2 Thanh Binh Nguyen 3 Marc Saake 1 James M. Provenzale 4,5
More informationOctober 23, Re: Gadolinium Toxicity from GBCAs. Dear Dr. Hamburg:
October 23, 2012 Commissioner Margaret A. Hamburg, M.D. U.S. Food and Drug Administration 10903 New Hampshire Avenue WO Bldg. 1, Room 2217 Silver Springs, MD 20993 Re: Gadolinium Toxicity from GBCAs Dear
More informationARTICLE IN PRESS European Journal of Radiology xxx (2011) xxx xxx
European Journal of Radiology xxx (2011) xxx xxx Contents lists available at ScienceDirect European Journal of Radiology journal homepage: www.elsevier.com/locate/ejrad Tolerability and diagnostic value
More informationClinical Study Nephrogenic Systemic Fibrosis Risk and Liver Disease
International Nephrology, Article ID 679605, 6 pages http://dx.doi.org/10.1155/2014/679605 Clinical Study Nephrogenic Systemic Fibrosis Risk and Liver Disease Robert F. Hanna, 1 Lee A. Finkelstone, 1 Daniel
More informationContrast Media Guidelines. To define general guidelines for the use of contrast media so that it is used appropriately and safely in imaging studies.
APPROVED BY: Director of Radiology Page 1 of 6 Purpose: Contrast Media Guidelines To define general guidelines for the use of contrast media so that it is used appropriately and safely in imaging studies.
More informationPublic Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended.
Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended Omniscan UK/W/063/pdWS/001 Rapporteur UK Finalisation procedure (day 20)
More informationADMELOG, NOVOLIN, NOVOLOG, and FIASP
ADMELOG, NOVOLIN, NOVOLOG, and FIASP Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationPRIMOVIST 5 ml, 7,5 ml, 10 ml
REGISTERED PACKAGE INSERT SCHEDULING STATUS S4 PROPRIETARY NAMES AND DOSAGE FORMS PRIMOVIST 5 ml, 7,5 ml, 10 ml Solution for injection COMPOSITION 1 ml of the MRI contract agent Primovist contains 181,43
More informationContrast controversies and confusion
Contrast controversies and confusion Mariya Kobi 1 ; Meir H Scheinfeld 1 ; Seymour Sprayregen 1 ; R Joshua Dym 2 * 1 Department of Radiology, Montefiore Medical Center, USA 2 Department of Radiology, Rutgers
More informationContrast. 5 Oral Contrast for CT...13
2 Contrast 1 GI Fluoroscopic Contrast...10 Adult Esophagram/Upper GI... 10 Pediatric Upper GI... 10 Enteroclysis... 10 Double-Contrast Barium Enema... 10 Single-Contrast Barium Enema... 10 Rectum and Pelvic
More informationWARNING LETTER. MD-Gastroview (Diatrizoate Meglumine and Diatrizoate Sodium Solution USP)
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration TRANSMITTED BY FACSIMILE Steven Hanley President Imaging Division Mallinckrodt Inc. 675 McDonnell Boulevard P.O.
More information